GlassScriptPhysician profile
Joshua J Mcfarlane
NPI 1184847055
$5,962.30
in general payments reported to CMS, 2019-2025
59 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $52.04 · 2020: $111 · 2021: $29.53 · 2022: $366 · 2023: $986 · 2024: $2,040 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,403.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $643.92 | 2021-2025 | Lynparza, Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $638.21 | 2019-2025 | |
| Pfizer INC. | $435.98 | 2019-2025 | |
| Janssen Biotech, INC. | $340.93 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $314.42 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Ipsen Biopharmaceuticals, INC | $240.89 | 2024-2025 | Onivyde, Somatuline Depot |
| E.R. Squibb & Sons, L.L.C. | $222.89 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Tersera Therapeutics LLC | $196.46 | 2023-2025 | Zoladex, Xermelo |
| Eisai INC. | $178.60 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.65 | 2022-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Daiichi Sankyo INC. | $169.37 | 2022-2025 | Enhertu, Injectafer |
| Genentech USA, INC. | $158.26 | 2023-2025 | Tecentriq, Avastin, Alecensa |
| Glaxosmithkline, LLC. | $140.74 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Genzyme Corporation | $136.96 | 2022-2025 | |
| Celgene Corporation | $102.59 | 2020-2024 | Pomalyst, Reblozyl |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $98.80 | 2023-2025 | |
| Incyte Corporation | $95.96 | 2022-2025 | Jakafi |
| Emd Serono, INC. | $94.74 | 2023-2025 | Tepmetko |
| Gilead Sciences, INC. | $91.68 | 2021-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $79.94 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $71.38 | 2023-2024 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $68.36 | 2023-2025 | Libtayo |
| Lilly USA, LLC | $68.23 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Genmab U.S., INC. | $66.71 | 2023-2025 | Epkinly |
| Abbvie INC. | $65.30 | 2025 | |
| Puma Biotechnology, INC. | $60.41 | 2024 | |
| Seagen INC. | $53.31 | 2019-2023 | Tivdak |
| Array Biopharma INC | $51.30 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Servier Pharmaceuticals LLC | $51.12 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $49.67 | 2022-2023 | Imbruvica |
| Taiho Oncology, INC. | $49.64 | 2024 | |
| Blue Earth Diagnostics | $48.93 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.92 | 2025 | |
| Amgen INC. | $47.00 | 2023 | Lumakras, Xgeva, Nplate |
| Pharmacosmos Therapeutics INC. | $45.96 | 2024-2025 | Monoferric |
| Adc Therapeutics America, INC. | $43.48 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $42.43 | 2022-2023 | Rezlidhia, Tavalisse |
| Deciphera Pharmaceuticals INC. | $38.97 | 2024-2025 | Qinlock |
| Progenics Pharmaceuticals, INC. | $36.66 | 2024-2025 | |
| Novocure INC. | $32.81 | 2023-2024 | Optune |
| Cti Biopharma Corp. | $32.78 | 2022 | |
| Caris Mpi, INC. | $31.57 | 2025 | Mi Cancer Seek |
| Apellis Pharmaceuticals, INC. | $29.47 | 2022-2023 | Empaveli |
| Alnylam Pharmaceuticals INC. | $27.90 | 2023 | Givlaari |
| Pharmaessentia USA Corporation | $23.90 | 2024 | Besremi |
| Stemline Therapeutics INC. | $23.44 | 2023 | Orserdu |
| Exelixis INC. | $23.38 | 2025 | Cabometyx |
| Beigene USA, INC. | $21.81 | 2023 | Brukinsa |
| Blueprint Medicines Corporation | $21.25 | 2025 | Ayvakit |
| G1 Therapeutics, INC. | $20.83 | 2023 | Cosela |
| Kite Pharma, INC. | $20.51 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.35 | 2024 | Ultomiris |
| Astellas Pharma US INC | $19.81 | 2024 | Padcev |
| Beone Medicines USA, INC. | $18.65 | 2025 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $16.99 | 2023 | Fotivda |
| Agios Pharmaceuticals, INC. | $14.08 | 2025 | Pyrukynd |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$950.94 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Mcfarlane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.